New Antiplatelet Therapy

New Antiplatelet Therapy
Apr 22, 2019 1:02pm

I've attached a pre-pub article describing a phase I trial of ACT017, a novel antiplatelet antibody fragment specific for glycoprotein VI, a platelet membrane collagen receptor. The manufacturers propose that ACT017 infusion can suppress platelet activity as part of coronary artery disease therapy with minimal bleeding risk. Clip or tap the citation for full information:

Voors-Pette C, Lebozec K, Dogterom P, et al. Safety and tolerability, pharmacokinetics, and pharmacodynamics of ACT017, an antiplatelet GPVI (glycoprotein VI) Fab first-in-human healthy volunteer trial. Arterioscler Thromb Vasc Biol. 2019;39: DOI: 10.1161/ATVBAHA.118.312314.

0 Comments

I've attached a pre-pub article describing a phase I trial of ACT017, a novel antiplatelet antibody fragment specific for glycoprotein VI, a platelet membrane collagen receptor. The manufacturers propose that ACT017 infusion can suppress platelet activity as part of coronary artery disease therapy with minimal bleeding risk. Clip or tap the citation for full information:

Voors-Pette C, Lebozec K, Dogterom P, et al. Safety and tolerability, pharmacokinetics, and pharmacodynamics of ACT017, an antiplatelet GPVI (glycoprotein VI) Fab first-in-human healthy volunteer trial. Arterioscler Thromb Vasc Biol. 2019;39: DOI: 10.1161/ATVBAHA.118.312314.

Leave A Comment

You must be logged in to Comment - Sign In